| dc.contributor | Казанский федеральный университет | |
| dc.contributor.author | Gaysina Leylya Rafaelevna | |
| dc.contributor.author | Bain Stephen | |
| dc.contributor.author | Bode Bruce | |
| dc.contributor.author | Clausen Jesper Ole | |
| dc.contributor.author | Coppieters Ken | |
| dc.contributor.author | Gumprecht Janusz | |
| dc.contributor.author | Hansen Troels Krarup | |
| dc.contributor.author | von Herrath Matthias | |
| dc.contributor.author | Mathieu Chantal | |
| dc.contributor.author | Morales Cristobal | |
| dc.contributor.author | Mosenzon Ofri | |
| dc.contributor.author | Segel Stine | |
| dc.contributor.author | Tsoukas George | |
| dc.contributor.author | Pieber Thomas R | |
| dc.date.accessioned | 2021-04-09T07:42:36Z | |
| dc.date.available | 2021-04-09T07:42:36Z | |
| dc.date.issued | 2021 | |
| dc.identifier.citation | Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial / von Herrath M. [at al.] // Lancet Diabetes Endrocrinol. - 2021. - Vol. 9, Is. 4. - P. 212-224. | |
| dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/163520 | |
| dc.description.abstract | ||
| dc.language.iso | en | |
| dc.relation.ispartofseries | The Lancet | |
| dc.rights | только для КФУ | |
| dc.subject | diabetes 1 type | |
| dc.title | Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial | |
| dc.type | Article | |
| dc.contributor.org | Институт фундаментальной медицины и биологии | |
| dc.description.pages | 212-224 | |
| dc.relation.ispartofseries-issue | 9 | |
| dc.pub-id | 251429 | |
| dc.identifier.doi | 10.1016/ S2213-8587(21)00019-X |